The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus

NCT01342042 on ClinicalTrials.gov · last registry update 2011-04-26

A small phase 2 — 36 participants, against a typical 110. Its estimated completion date, December 2011, has passed with no update to the record. Primary outcome, as filed: To compare treatment arms in terms of change from baseline to endpoint in HbA1c. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Sponsor type: Industry
Enrollment: 36
Started: 2011-03
Primary completion: 2011-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

To compare treatment arms in terms of change from baseline to endpoint in HbA1c

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.